¿Cómo actuar? | 27 ENE 15

Tratamiento antitrombótico en pacientes sometidos a procedimientos invasivos

Este artículo proporciona enfoques y orientaciones para pacientes sometidos a procedimientos invasivos mientras reciben tratamiento antitrombótico.
Autor/a: Dres. Baron TH, Kamath PS, McBane RD N Engl J Med 2013;368:2113-24.
INDICE:  1. Artículo | 2. Referencias
Referencias


1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics —2012 update. Circulation 2012; 125(1):e2- e220. [Erratum, Circulation 2012;125(22):e1002.]
2. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:2 Suppl:e326Se350S. [Erratum, Chest 2012;141:1129.]
3. Boustière C, Veitch A, Vanbiervliet G, et al. Endoscopy and antiplatelet agents: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2011; 43:445-61.
4. Anderson MA, Ben-Menachem T, Gan SI, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009;70:1060-70.
5. Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008; 57:1322-9.
6. Altenburg A, Haage P. Antiplatelet and anticoagulant drugs in interventional radiology. Cardiovasc Intervent Radiol 2012; 35:30-42.
7. Perry DJ, Noakes TJ, Helliwell PS. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J 2007; 203:389-93.
8. Malloy PC, Grassi CJ, Kundu S, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2009; 20:7 Suppl:S240-S249.
9. Godfrey EM, Godfrey AL, Perry DJ, Shaw AS. Don’t be a clot: a radiologist’s guide to haemostasis including novel antiplatelet and anticoagulant therapies. Clin Radiol 2011; 66:693-700.
10. Sié P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Arch Cardiovasc Dis 2011; 104:669-76.
11. Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. J Can Dent Assoc 2009; 75:41.
12. Korte W, Cattaneo M, Chassot PG, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease. Thromb Haemost 2011;105:743-9.
13. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2011; 57(11):e101-e198.
14. Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:2 Suppl:e120S-e151S.
15. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:2 Suppl:e89S-e119S.
16. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-70.
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263-72.
18. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:6 Suppl:844S-886S.
19. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;94: 635-41.
20. Hering D, Piper C, Bergemann R, et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest 2005; 127:53-9.
21. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:2 Suppl:e419S-e494S. [Erratum, Chest 2012; 142:1698-1704.]
22. de Jong PG, Coppens M, Middeldorp S. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term. Br J Haematol 2012; 158:433-41.
23. McBane RD, Wysokinski WE, Daniels PR, et al. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb
Vasc Biol 2010; 30:442-8.
24. Tafur AJ, Wysokinski WE, McBane RD, et al. Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Oncol 2012; 23: 1998-2005.
25. Lyman GH, Kuderer NM. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Thromb Res 2010; 125:Suppl 2: S120-S127.
26. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007; 115:813-8.
27. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning.” J Am Coll Cardiol 2010;56: 321-41.
28. Kleiman NS. Grabbing the horns of a dilemma: the duration of dual antiplatelet therapy after stent implantation. Circulation 2012; 125:1967-70.
29. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Circulation 2011;124(23):e574-e651. [Erratum, Circulation 2012; 125(8):e412.]
30. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update). J Am Coll Cardiol 2012; 60:645-81.
31. Kastrati A, Byrne RA, Schulz S. Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation? JACC Cardiovasc Interv 2011; 4:1129-32.
32. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362:1374-82.
33. Tafur AJ, McBane R 2nd, Wysokinski WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 2012; 10:261-7.
34. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3:692-4.
35. Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002; 55:775-9.
36. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010;35:64-101.
37. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anaesthesia and antithrombotic agents. Eur J Anaesthesiol 2010; 27:999-1015.
38. Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71:446-54.
39. Douketis JD. Contra: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery.” Thromb Haemost 2012; 108:210-2.
40. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368:2084-93.
41. Spyropoulos AC. Pro: “Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery.” Thromb Haemost 2012;108: 213-6.
42. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012;126:1630-9.
43. BRIDGE Study Investigators. Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure? Circulation 2012;125(12): e496-e498.
44. Wysokinski WE, McBane RD II. Periprocedural bridging management of anticoagulation. Circulation 2012; 126:486-90.
45. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-18.
46. Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost 2012; 107:803-5.
47. Kozek-Langenecker SA. Perioperative coagulation monitoring. Best Pract Res Clin Anaesthesiol 2010; 24:27-40.
48. Schulman S, Elbazi R, Zondag M, O’Donnell M. Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. Thromb J 2008; 16:15.
49. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:2 Suppl:e152Se184S.
50. Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res 2012; 130:833-40.
51. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87:Suppl 1:S141-S145. [Erratum, Am J Hematol 2012;87:748.]
52. Hart RG, Eikelboom JW, Ingram AJ, Herzog CA. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012; 8:569-78.
53. Dzik WS. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion 2012; 52:Suppl 1: 45S-55S.
54. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336:1506-11.
55. Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis 2007; 24:93-7.
56. Landenhed M, Johansson M, Erlinge D, Olsson ML, Bjursten H. Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. Scand Cardiovasc J 2010; 44:100-6.
57. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123:1436-50.
58. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126:343-8. [Erratum, Circulation 2012;126(10):e160.]
59. Carmignani L, Picozzi S, Bozzini G, et al. Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis. Transfus Apher Sci 2011; 45:275-80.
60. Atwell TD, Smith RL, Hesley GK, et al. Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. AJR Am J Roentgenol 2010; 194:784-9.
61. Wahidi MM, Garland R, Feller-Kopman D, Herth F, Becker HD, Ernst A. Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. Chest 2005; 127:961-4.
62. Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther 2007; 25:579-84.
63. Usman MH, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol 2009; 103:1107-12.
64. Geng DF, Liu M, Jin DM, Wu W, Deng J, Wang JF. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology 2012; 122:148-57.
65. Lansberg MG, O’Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:2 Suppl: e601S-e636S.
66. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:2 Suppl:7S-47S. [Erratum, Chest 2012;141:1129.]
67. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:6 Suppl:299S-339S.
68. Desborough M, Stanworth S. Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures. Transfusion 2012; 52:Suppl 1:20S-29S.
69. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-9.
70. Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 2009; 7:Suppl 1:107-10.
71. MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:2 Suppl:e1S-e23S.
 

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024